Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K; FLAURA2 Investigators. Planchard D, et al. N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8. N Engl J Med. 2023. PMID: 37937763 Clinical Trial.
Service Evaluation of MyChristie-MyHealth, an Electronic Patient-Reported Outcome Measure Integrated Into Clinical Cancer Care.
Shipman LA, Price J, Abdulwahid D, Bayman N, Blackhall F, Califano R, Chan C, Coote J, Eaton M, Fenemore J, Gomes F, Harris M, Halkyard E, Lindsay C, Neal H, McEntee D, Sheikh H, Summers Y, Taylor P, Woolf D, Yorke J, Faivre-Finn C. Shipman LA, et al. Among authors: califano r. JCO Clin Cancer Inform. 2024 Apr;8:e2300162. doi: 10.1200/CCI.23.00162. JCO Clin Cancer Inform. 2024. PMID: 38574311
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Lee SM, Schulz C, Prabhash K, Kowalski D, Szczesna A, Han B, Rittmeyer A, Talbot T, Vicente D, Califano R, Cortinovis D, Le AT, Huang D, Liu G, Cappuzzo F, Reyes Contreras J, Reck M, Palmero R, Mak MP, Hu Y, Morris S, Höglander E, Connors M, Biggane AM, Vollan HK, Peters S. Lee SM, et al. Among authors: califano r. Lancet. 2023 Aug 5;402(10400):451-463. doi: 10.1016/S0140-6736(23)00774-2. Epub 2023 Jul 6. Lancet. 2023. PMID: 37423228 Clinical Trial.
Novel therapeutic strategies for recurrent SCLC.
Moliner L, Zhang B, Lamberti G, Ardizzoni A, Byers LA, Califano R. Moliner L, et al. Among authors: califano r. Crit Rev Oncol Hematol. 2023 Jun;186:104017. doi: 10.1016/j.critrevonc.2023.104017. Epub 2023 May 5. Crit Rev Oncol Hematol. 2023. PMID: 37150311 Review.
Experience With the Routine Use of Electronic Patient-Reported Outcome Measures for Patients With Lung Cancer.
Crockett C, Price J, Pham M, Abdulwahid D, Bayman N, Blackhall F, Bostock L, Califano R, Chan C, Coote J, Cove-Smith L, Eaton M, Fenemore J, Gomes F, Harris M, Halkyard E, Hughes S, Lindsay C, Neal H, McEntee D, Pemberton L, Sheikh H, Summers Y, Taylor P, Woolf D, Yorke J, Faivre-Finn C. Crockett C, et al. Among authors: califano r. JCO Clin Cancer Inform. 2023 Apr;7:e2200150. doi: 10.1200/CCI.22.00150. JCO Clin Cancer Inform. 2023. PMID: 37071029 Free PMC article.
128 results